A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors. (SIGNAL-IO 301)
A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Continuous Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced/Metastatic Solid Tumors
調査の概要
状態
条件
詳細な説明
This is a multicenter, open-label, randomized (1:1) trial designed to evaluate whether ctDNA-guided interruption of immune-checkpoint inhibitor (ICI) therapy provides comparable survival to standard of care (SoC) continuous ICI therapy in patients with histologically confirmed advanced/metastatic non-small cell lung cancer (NSCLC), melanoma, microsatellite instability-high (MSI-High)/Deficient Mismatch Repair (dMMR) colorectal cancer (CRC), renal cell carcinoma (RCC) and other solid tumors.
Patients meeting eligibility criteria are randomized into two arms:
Arm A (SoC Continuous ICI): Participants will continue current ICI therapy per SoC.
Arm B (ctDNA-Guided Intermittent ICI): Participants will interrupt ICI therapy upon randomization and pursue monitoring that includes serial ctDNA testing. They will reinitiate the same ICI therapy (monotherapy or dual-ICI therapy as documented at enrollment) if they become ctDNA-positive without evidence of radiographic progression. Following reinitiation, ICI therapy may again be interrupted after achievement of ≥ 2 consecutive ctDNA-negative results and subsequently re-initiated upon recurrence of ctDNA positivity without evidence of radiographic progression. This cycle of ctDNA-guided interruption and reinitiation (maximum of 2 ICI interruptions) may continue until radiographic progression is documented. Upon radiographic progression, treatment will be determined by the treating physician in accordance with SoC.
Participants will be followed prospectively from randomization through the end of the treatment monitoring phase for up to 36 months and then survival follow-up, up to 5 years. Participants in both arms will undergo response assessments including imaging (CT/MRI) (BICR review) and ctDNA testing performed q12 weeks; PRO (QLQ-C30, FACT-ICM, PRO-CTCAE & EQ-5D-5L) data collection (q12 weeks); and continued toxicity assessment reviewed per CTCAE v6.0 at each visit and unscheduled contacts.
All data are collected under a unified electronic data-capture (EDC) system with site entry verified by central data management. Core data streams include clinical visits, imaging, ctDNA testing, safety events, PROs, and healthcare resource consumption.
Digitized slides of tissues (obtained either from commercial Signatera tests or upon confirmatory Signatera testing) may be collected for future research. Imaging data collected as part of study procedures may also be centrally archived for exploratory imaging and radiomic analyses.
Optional biobanking: Two 10 mL Streck blood samples may be collected at enrollment and at confirmed disease progression, defined as radiographic progression (per RECIST 1.1), for exploratory biomarker analyses.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Amanda L Andersen
- 電話番号:844-778-4700
- メール:aandersen@natera.com
研究連絡先のバックアップ
- 名前:Brooke Cormane
- 電話番号:844-778-4700
- メール:bcormane@natera.com
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
General inclusion criteria includes the following selection criteria to be eligible for inclusion in any aspect of the study. Eligibility will be assessed by the investigator:
- Signed Informed consent
- Age ≥ 18 years
- ECOG 0-2.
Histologically confirmed advanced/metastatic solid tumors including:
- Melanoma: Unresectable recurrent, advanced, or metastatic
- NSCLC: Advanced or metastatic
- MSI-High/dMMR CRC: Metastatic
- RCC: Unresectable recurrent, advanced, or metastatic
- Other: Metastatic solid tumors
Received first line ICI monotherapy or dual-ICI therapy (e.g., PD-1/CTLA-4 combination therapy) for a minimum of 12 months (maximum of 15 months) for NSCLC, RCC & other metastatic solid tumors, or for a minimum of 6 months (maximum of 9 months) for melanoma and MSI-High /dMMR CRC. Exceptions permitted:
- For patients with NSCLC: First line platinum-based chemo-ICI regimens if on maintenance ICI +/- pemetrexed.
- For patients with melanoma: nivolumab/relatlimab is permissible.
- Radiographic CR/PR: Participants must have CR or PR at the last assessment performed within 6 weeks before randomization according to RECIST v1.1 using a diagnostic CT and/or MRI. Radiographic assessment must be confirmed by the BICR prior to randomization.
Known ctDNA-negative with a tissue-informed assay
- ≥ 2 consecutive ctDNA-negative results at least 6 weeks apart; last test within 1 month of enrollment.
- Note: A confirmatory Signatera Genome negative test must be completed at enrollment if previous ctDNA testing performed for clinical care was done with a test other than Signatera Genome.
Adequate organ function:
- Hematology: ANC ≥1500/μL; Platelets ≥100000/μL;Hemoglobin ≥9.0g/dL;
- Renal: Serum Cr ≤1.5×ULN or calculated CrCl ≥60 mL/min (using Cock-Gault formula);
- Hepatic: Total bilirubin ≤1.5 ×ULN or, for participants with total bilirubin levels >1.5×ULN, direct bilirubin within normal limits; AST (SGOT) and ALT (SGPT) ≤2.5×ULN;
- Coagulation: INR or PT, activated partial thromboplastin time (APTT) ≤1.5×ULN Note: Laboratory assessments performed as part of standard of care evaluations during immunotherapy treatment administration may be used to satisfy these eligibility criteria, provided they are obtained within 28 days of enrollment.
- Recovery to baseline or ≤ Grade 1 common terminology criteria for adverse events (CTCAE) v6 from AE(s) related to any prior treatments unless AE(s) are deemed clinically non-significant (e.g., Grade 2 alopecia) by the Investigator and/or stable on supportive therapy.
- No prior malignancy, with the exception of basal cell carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the skin, or in situ cancer, or has undergone potentially curative therapy with no evidence of that disease recurrence for 5 years since completion of definitive therapy
- Participants must be willing and able to comply with study visits, treatment plans, laboratory tests, and other study procedures
- Women of child-bearing potential (WOCBP) and male participants partnering with WOCBP must agree to use highly effective contraception during the treatment phase and at least 180 days post last dose
- Patients must be willing to discontinue clinically-directed ctDNA testing for treatment response monitoring during the period of clinical trial testing as dictated by the protocol.
Exclusion Criteria
Patients are not eligible for the study if they meet any of the following criteria, as assessed by the investigator:
- Available alternate treatment options with curative intent, e.g. surgery and / or RT and / or Chemotherapy.
- Symptomatic or progressing CNS metastases; or presence of leptomeningeal disease.
- Patient has active autoimmune disease that required systemic treatment in the past 2 years, is immunocompromised in the opinion of the Investigator, or is receiving systemic immunosuppressive treatment. (Note: Participants with splenectomy are allowed.) Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc) is not considered a form of systemic treatment.
- Patient is receiving systemic steroid therapy ≤3 days prior to enrollment or receiving any other form of immunosuppressive medication with the exception of daily steroid replacement therapy. Note: Use of inhaled corticosteroids, local steroid injection, or steroid eye drops is allowed.
- Had allogeneic tissue/solid organ transplantation.
- Interstitial lung disease or history of pneumonitis that has required oral or IV steroids. Note: Patients with lymphangitic carcinomatosis secondary to NSCLC can be considered as eligible.
- Has received or will receive a live vaccine within 30 days prior to enrollment (seasonal flu vaccines that do not contain live vaccine are permitted).
- Active infection requiring intravenous systemic therapy.
- Known history of human immunodeficiency virus (HIV).
- Known active Hepatitis B or C.
- Pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the study.
- Currently participating or has participated in a study of an investigational agent or using an investigational device within 4 weeks of enrollment.
- Use of any commercial ctDNA or liquid biopsy monitoring outside of the study protocol during the treatment monitoring phase within the protocol.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:SOC Continuous ICI
Participants will continue the current ICI therapy, per approved product label and / or treating investigator's clinical judgement. Standard infusion visits are maintained for the total of 2 years or until radiographic progression, unacceptable toxicity, or withdrawal of consent. |
The test is used to monitor for disease recurrence.
|
|
実験的:ctDNA-Guided Intermittent ICI
Participants will interrupt ICI therapy upon randomization and pursue monitoring that includes serial ctDNA testing.
They will reinitiate the same ICI therapy (monotherapy or dual-ICI therapy as documented at enrollment) if they become ctDNA-positive without evidence of radiographic progression.
Following reinitiation, ICI therapy may again be interrupted after achievement of ≥ 2 consecutive ctDNA-negative results and subsequently re-initiated upon recurrence of ctDNA positivity without evidence of radiographic progression.
This cycle of ctDNA-guided interruption and reinitiation (maximum of 2 ICI interruptions) may continue until radiographic progression is documented.
Upon radiographic progression, treatment will be determined by the treating physician in accordance with SoC.
|
The test is used to monitor for disease recurrence.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
To demonstrate that ctDNA-guided intermittent ICI therapy results in at least 50% of patients who do not reinitiate systemic therapy prior to 6 months from randomization.
時間枠:6 months from randomization
|
6 months from randomization
|
|
To demonstrate that ctDNA-guided intermittent ICI therapy is non-inferior to SoC continuous ICI therapy as measured by 36 month OS in advanced/metastatic solid tumor patients.
時間枠:3 years from randomization to death from any cause
|
3 years from randomization to death from any cause
|
二次結果の測定
結果測定 |
時間枠 |
|---|---|
|
To compare ctDNA-guided intermittent ICI therapy to SoC continuous ICI therapy as measured by 36 month progression-free survival (PFS) (blinded independent central review [BICR] assessed) in advanced/metastatic solid tumor patients.
時間枠:3 years from randomization to the first occurrence of disease progression measured by RECIST 1.1 or death from any cause, whichever occurs first
|
3 years from randomization to the first occurrence of disease progression measured by RECIST 1.1 or death from any cause, whichever occurs first
|
|
To compare the tolerability between the ctDNA-guided intermittent ICI therapy and SoC continuous ICI therapy using the Common Terminology Criteria for Adverse Events (CTCAE) v6.0.
時間枠:From randomization to Year 3
|
From randomization to Year 3
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Caitlin Shonewolf, MD、Natera, Inc.
出版物と役立つリンク
一般刊行物
- Andre T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, Smith D, Garcia-Carbonero R, Benavides M, Gibbs P, de la Fouchardiere C, Rivera F, Elez E, Bendell J, Le DT, Yoshino T, Van Cutsem E, Yang P, Farooqui MZH, Marinello P, Diaz LA Jr; KEYNOTE-177 Investigators. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. N Engl J Med. 2020 Dec 3;383(23):2207-2218. doi: 10.1056/NEJMoa2017699.
- Eroglu Z, Krinshpun S, Kalashnikova E, Sudhaman S, Ozturk Topcu T, Nichols M, Martin J, Bui KM, Palsuledesai CC, Malhotra M, Olshan P, Markowitz J, Khushalani NI, Tarhini AA, Messina JL, Aleshin A. Circulating tumor DNA-based molecular residual disease detection for treatment monitoring in advanced melanoma patients. Cancer. 2023 Jun 1;129(11):1723-1734. doi: 10.1002/cncr.34716. Epub 2023 Mar 4.
- Zalcman G, Madroszyk A, Guenzi E, Dayen C, Molinier O, Egenod T, Pote N, Debieuvre D, Beaucaire-Danel S, Dixmier A, Pichon E, Galland-Girodet S, Giroux-Leprieur E, Cloarec N, Cadranel J, Otto J, Romand P, Favier L, Martinez S, Mascaux C, Odier L, Cortot A, Audigier-Valette C, Langlais A, Amour E, Morin F, Antoine M, Gounant V, Westeel V, Toffart AC. Four-Year Outcomes of First-Line Nivolumab Plus Ipilimumab for 6 Months Versus Continuation in Patients With Advanced NSCLC: Results of the Randomized IFCT-1701 "DICIPLE" Phase III Trial. J Thorac Oncol. 2026 Jun;21(6):103609. doi: 10.1016/j.jtho.2026.103609. Epub 2026 Feb 12.
- Vokes NI, Pan K, Le X. Efficacy of immunotherapy in oncogene-driven non-small-cell lung cancer. Ther Adv Med Oncol. 2023 Mar 18;15:17588359231161409. doi: 10.1177/17588359231161409. eCollection 2023.
- Vokes N, Gandara D, Sezer A, Kilickap S, Gümüş M, Bondarenko I, Özgüroğlu M, Gogishvili M, Turk HM, Cicin I, Bentsion D. Circulating tumor DNA (ctDNA) dynamics and survival outcomes in patients with advanced NSCLC and high (> 50%) PD-L1 expression, randomized to cemiplimab vs chemotherapy. In ASCO Annual Meeting, Chicago, IL 2023 Jun.
- Sun L, Bleiberg B, Hwang WT, Marmarelis ME, Langer CJ, Singh A, Cohen RB, Mamtani R, Aggarwal C. Association Between Duration of Immunotherapy and Overall Survival in Advanced Non-Small Cell Lung Cancer. JAMA Oncol. 2023 Aug 1;9(8):1075-1082. doi: 10.1001/jamaoncol.2023.1891.
- Nakamura Y, Watanabe J, Akazawa N, Hirata K, Kataoka K, Yokota M, Kato K, Kotaka M, Kagawa Y, Yeh KH, Mishima S, Yukami H, Ando K, Miyo M, Misumi T, Yamazaki K, Ebi H, Okita K, Hamabe A, Sokuoka H, Kobayashi S, Laliotis G, Aushev VN, Sharma S, Jurdi A, Liu MC, Aleshin A, Rabinowitz M, Bando H, Taniguchi H, Takemasa I, Kato T, Kotani D, Mori M, Yoshino T, Oki E. ctDNA-based molecular residual disease and survival in resectable colorectal cancer. Nat Med. 2024 Nov;30(11):3272-3283. doi: 10.1038/s41591-024-03254-6. Epub 2024 Sep 16.
- Martinez-Vila C, Teixido C, Martin R, Aya F, Sudhaman S, Budde GL, Gonzalez-Navarro EA, Alos L, Castrejon N, Ortiz JB, Krainock M, Liu MC, Arance A. Personalized Circulating Tumor DNA Assay to Assess Long-Term Clinical Benefit in Patients with Advanced Melanoma. Cancers (Basel). 2025 Nov 27;17(23):3804. doi: 10.3390/cancers17233804.
- Larkin J, Sileni VC, Marqueste CG, Rutkowski P, Medina TM, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, Queirolo P. LBA43 10-y survival outcomes from the phase III CheckMate 067 trial of nivolumab plus ipilimumab in advanced melanoma. Annals of Oncology. 2024 Sep 1;35:S1234-5.
- Botta GP, Abdelrahim M, Drengler RL, Aushev VN, Esmail A, Laliotis G, Brewer CM, George GV, Abbate SM, Chandana SR, Tejani MA, Malla M, Bansal D, Rivero-Hinojosa S, Spickard E, McCormick N, Cecchini M, Lacy J, Fei N, Kasi PM, Kasi A, Dayyani F, Hanna DL, Sharma S, Malhotra M, Aleshin A, Liu MC, Jurdi A. Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma. Oncologist. 2024 Oct 3;29(10):859-869. doi: 10.1093/oncolo/oyae155.
- Bogani G, Cinquini M, Signorelli D, Pizzutilo EG, Romano R, Bersanelli M, Raggi D, Alfieri S, Buti S, Bertolini F, Bonomo P, Marandino L, Rizzo M, Monteforte M, Aiello M, Tralongo AC, Torri V, Di Donato V, Giannatempo P. A systematic review and meta-analysis on the optimal treatment duration of checkpoint inhibitoRS in solid tumors: The OTHERS study. Crit Rev Oncol Hematol. 2023 Jul;187:104016. doi: 10.1016/j.critrevonc.2023.104016. Epub 2023 May 6.
- Ben-David R, Lidagoster S, Geduldig J, Kolanukuduru KP, Elkun Y, Tillu N, Mandel A, Almoflihi M, Kaufmann B, Attalla K, Mehrazin R, Wiklund P, Sfakianos JP. Undetectable pre-radical cystectomy circulating tumour DNA status predicts improved oncological outcomes. BJU Int. 2025 Mar;135(3):473-480. doi: 10.1111/bju.16556. Epub 2024 Oct 16.
- Basu A, Au C, Kommalapati A, Kandala H, Sudhaman S, Mahmood T, Carson C, Pajak N, Dutta P, Calhoun M, Malhotra M, ElNaggar AC, Liu MC, Ferguson Iii J, Peyton C, Rais-Bahrami S, Tan A. Longitudinal Testing of Circulating Tumor DNA in Patients With Metastatic Renal Cell Carcinoma. JCO Precis Oncol. 2024 Dec;8:e2400667. doi: 10.1200/PO-24-00667. Epub 2024 Dec 18.
- Afzal MZ, Corea-Dilbert FE, Wankel B, Palmer JP, Pirruccello JP, Kale S, Sharma A, Lu Z, Ibrahim S, Cao Y, Sarwar T. Utility of circulating tumor DNA as a tool to detect minimal residual disease in patients with metastatic cancer and durable response following treatment with immune checkpoint inhibitors. American Society of Clinical Oncology Annual Meeting. 2023. e21563-e21563.
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- 26-107-NCP
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。